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Background: Restrictive respiratory failure is a major cause of morbidity and mortal-
ity in neuromuscular diseases (NMD). Home mechanical ventilation (HMV) is used to 
treat hypoventilation, and its efficiency is mostly assessed by daytime blood gases or 
nocturnal oxygen saturation monitoring (SpO2). Non-invasive transcutaneous measure 
of CO2 (TcCO2) allows to directly assess nocturnal hypercapnia and to detect residual 
hypoventilation with a higher sensitivity than SpO2. We aimed to compare the prognostic 
value of nocturnal SpO2 and TcCO2 in ventilated adult NMD patients.
Methods: All consecutive capno-oximetries performed between 2010 and 2011 in ven-
tilated adult NMD patients were analyzed retrospectively. Concomitant blood gas anal-
ysis and lung function data were collected. Patients on oxygen therapy were excluded. 
Nocturnal hypoxemia and hypercapnia (using four different definitions) at baseline were 
compared in their ability to predict mortality and respiratory events requiring ICU admis-
sion during follow-up.
results: Data from 55 patients were analyzed (median age 28 [interquartile range: 
25–36.5] years; 71% Duchenne muscular dystrophy; vital capacity 12 [7–27]% of 
predicted; 51% tracheostomy). Capno-oxymetry showed hypoxemia in 14.5% and 
hypercapnia in 12.7–41.8%, according to the used definition. Over a follow-up lasting 
up to 5 years (median 4.0 [3.6–4.5] years), we observed 12 deaths and 20 respiratory 
events requiring ICU admission. Hypercapnia was significantly associated with the study 
Abbreviations: CO2, carbon dioxide; DMD, Duchenne muscular dystrophy; HMV, home mechanical ventilation; MD1, 
myotonic dystrophy type 1 (Steinert’s disease); NMD, neuromuscular diseases; PaCO2, partial arterial pressure of CO2; PE 
max, maximal expiratory pressure; PI max, maximal inspiratory pressure; SpO2, oxygen saturation; TcCO2, transcutaneous 
measure of CO2; VC, respiratory vital capacity.
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outcomes, with TcCO2 > 49 mmHg during ≥10% of the time being the best definition, 
while hypoxemia was not.
conclusion: Our data show for the first time that residual hypoventilation, assessed by 
capnometry, is significantly associated with negative outcomes in adult ventilated NMD 
patients, while oximetry is not. Accordingly, we suggest capnometry to be included in 
the systematic assessment of HMV efficiency in NMD patients.
clinicalTrials.gov identifier: NCT02551406.
Keywords: home mechanical ventilation, neuromuscular disease, restrictive respiratory failure, nocturnal 
hypoventilation, transcutaneous capno-oximetry, prognosis
inTrODUcTiOn
Neuromuscular diseases (NMD) are a heterogeneous group of 
rare diseases involving various components of the nervous sys-
tem, including the respiratory muscles. The progressive weakness 
of the respiratory muscle pump results in restrictive respiratory 
failure and represents a major cause of morbidity and mortality in 
these pathologies (1–5). Long-term home mechanical ventilation 
(HMV) is effective to treat alveolar hypoventilation and cur-
rently represents one of the few available treatments improving 
the clinical course of NMD patients (2–4, 6–8). Once HMV is 
implemented, a regular follow-up is required to assure optimal 
tolerance and efficiency of the treatment. Besides the assessment 
of blood gases, HMV monitoring can be performed with differ-
ent approaches with increasing complexity grade, ranging from 
simple tools, such as oximetry, to the most comprehensive sleep 
recording using in-hospital polysomnography (9). A manage-
ment strategy was recently proposed, consisting of a simple initial 
screening based on nocturnal oxygen saturation monitoring 
(SpO2), followed by additional investigations in case of patho-
logical findings (9). Non-invasive transcutaneous measure of CO2 
(TcCO2) was found to have acceptable accuracy for estimating 
PaCO2 over several hours in stable home-ventilated patients (10, 
11) and showed a higher sensitivity than SpO2 to detect residual 
hypoventilation in NMD patients (12, 13).
Current recommendations about monitoring and adjustment 
of HMV repose on expert opinions, since scientific literature 
comparing different strategies to assess HMV efficiency on their 
impact on hard clinical endpoints is still lacking (9, 14).
The aim of our study was to compare the prognostic value of 
SpO2 and TcCO2 in unselected ventilated adult NMD patients.
MaTerials anD MeThODs
Patients
Data were collected retrospectively from the charts of NMD 
adults, followed at the Home Mechanical Ventilation Unit of the 
Raymond Poincare University Hospital, Garches, France. All 
consecutive capno-oximetries performed electively on mechani-
cally ventilated patients between June 2009 and July 2011 were 
reviewed, and the oldest recording of each patient was retained 
for analysis. Patients on oxygen therapy were excluded. The study 
was conducted in accordance with the declaration of Helsinki and 
was approved by the French national regulatory board (CNIL, 
No. 1890638). ClinicalTrials.gov Identifier: NCT02551406.
capno-Oximetry
Overnight, continuous non-invasive TcCO2 and oxygen 
saturation (SpO2) were recorded simultaneously using a Digital 
Monitoring System (SenTec, Therwil, Switzerland) equipped with 
a combined Severinghaus-type TcCO2 electrode and SpO2 sensor 
(V-Sign, SenTec, Therwil, Switzerland). As recommended by the 
manufacturer, the electrode was calibrated in the built-in docking 
station before and after each measurement, using a service gas 
(mixture of 8% CO2, 12% O2, and 80% N2), allowing the measured 
TcCO2 values to be corrected for calibration drift. All studies 
were visually inspected to exclude periods with artifacts from 
the results, which represented in mean 1% of the recording time 
(range 0–4%).
Daytime Blood gases
According to routine clinical practice in the unit, daytime blood 
gas values were obtained on the morning following the capno-
oxymetry. The blood sample was drawn at rest and immediately 
carried in an ice bag to the central chemical laboratory of the 
hospital, were it was analyzed using routine methods with strin-
gent quality controls.
Definition of hypoventilation
Five different criteria were used to define residual hypoventilation 
during HMV, one reposing on oximetry and four on TcCO2 with 
different cut-offs:
 – SpO2 < 90% during ≥10% of the total recording time (“hypox-
emia”) (9, 12);
 – peak TcCO2 > 49 mmHg (“hypercapnia[1]”) (7, 12);
 – TcCO2 > 49 mmHg during ≥10% of the total recording time 
(“hypercapnia[2]”);
 – peak TcCO2 > 55 mmHg (“hypercapnia[3]”);
 – TcCO2 > 55 mmHg for ≥10 min or increase in TcCO2 ≥ 10 mmHg 
(in comparison to an awake supine value) to a value exceeding 
50 mmHg for ≥10 min (“hypercapnia[4]”) (15).
Outcomes
We considered mortality and acute respiratory events requiring 
ICU admission as outcomes of interest for the present analysis. 
TaBle 1 | characteristics of the study population.
N (%) or median [iQr]
Parameters
Number of patients 55
Pathology (N, %)
 – DMD 39 (70.9%)
 – MD1 5 (9.1%)
 – Other 11 (20.0%)
Age (years) 28 [25–36.5]
Weight (kg) 45.0 [36.0–60.5]
BMI (kg/m2) 17.0 [14.6–24.2]
Follow-up (years) 4.0 [3.6–4.5]
Deaths (N, %) 12 (21.8%)
ICU admissions (N, %) 20 (36.4%)
respiratory parameters
VC sitting (%pred) 12 [7–27]
VC supine (%pred) 10 [5–20]
PI max (cmH2O) 12 [3–27]
PE max (cmH2O) 10 [5–24]
Mechanical ventilation
Volumetric mode (N, %) 40 (72.7%)
Tracheostomy (N, %) 28 (50.9%)
Daily HMV duration (h) 22.5 [9.0–24.0]
Daytime blood gases
pH 7.42 [7.39–7.47]
PaO2 (kPa) 11.3 [9.3–15.0]
PaCO2 (kPa) 4.78 [4.04–5.46]
Bicarbonates (mmol/l) 24.7 [21.6–27.2]
nocturnal capno-Oximetry
Duration of the recording (min) 473 [459–475]
Mean oxygen saturation (%) 96 [95–98]
Mean nocturnal TcCO2 (mmHg) 39.8 [30.4–45.0]
Max nocturnal TcCO2 (mmHg) 48.1 [37.4–52.5]
DMD, Duchenne muscular dystrophy; MD1, myotonic dystrophy type 1 (Steinert’s 
disease); BMI, body mass index; VC, vital capacity; %pred, percentage of the 
predicted value; PI max, maximal inspiratory pressure; PE max, maximal expiratory 
pressure; HMV, home mechanical ventilation; PaCO2, partial arterial pressure of CO2; 
PaO2, partial arterial pressure of O2; TcCO2, transcutaneous measure of CO2; IQR, 
interquartile range.
FigUre 1 | Prevalence of residual hypoventilation according to the 
different definitions. Hypoventilation definitions: “hypoxemia”: oxygen 
saturation (SpO2) < 90% during ≥10% of the total recording time; 
“hypercapnia[1]”: peak transcutaneous CO2 (TcCO2) > 49 mmHg; 
“hypercapnia[2]”: TcCO2 > 49 mmHg during ≥10% of the total recording 
time; “hypercapnia[3]”: peak TcCO2 > 55 mmHg, “hypercapnia[3]”: 
TcCO2 > 55 mmHg for ≥10 min, or increase in TcCO2 ≥ 10 mmHg in 
comparison to baseline to a value exceeding 50 mmHg for ≥10 min.
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Ventilated NMD patients are hospitalized at least annually for 
follow-up in our Unit, and at each visit, details on undercurrent 
hospitalizations in other hospitals are collected in the medical 
chart. In case of death, the furnisher of the home ventilator 
immediately reports the interruption of treatment to our Unit, 
and as much of informations as possible are collected.
statistical analysis
Continuous variables were described by median and interquartile 
range (IQR); dichotomous or categorical variables were described 
by number of subjects and percentage. Single outcomes were ana-
lyzed by computing cumulative incidence curves and compared 
using Gray’s test, and the event-free survival was analyzed by com-
puting Kaplan–Meier curves. Statistical analysis was conducted 
using R statistical software (R Core Team, www.r-project.org).
resUlTs
Data from 55 ventilated NMD adults were available. Most of 
the patients had Duchenne muscular dystrophy and a severe 
restrictive respiratory failure (median vital capacity 12% of 
predicted [IQR 7–27]), requiring 24-h mechanical ventilation in 
45.5% of the cases. The characteristics of the study population are 
detailed in Table 1.
capno-Oximetry
Eight patients (14.5%) were detected to have hypoxemia, while 
prevalence of hypercapnia ranged from 12.7 to 41.8%, according 
to the used criterion (Figure 1). Three to seven patients showed 
both hypoxemia and hypercapnia, depending on the criterion 
used to define hypercapnia.
Outcomes
Over a follow-up period lasting up to 5 years (median 4.0 [IQR 
3.6–4.5] years), we observed 12 deaths and 20 acute respiratory 
events requiring ICU admission. The overall mortality was 5.5% 
at 2  years and 33.0% at 5  years, without significant difference 
between the study groups.
Respiratory events requiring ICU admission were sig-
nificantly associated with residual hypercapnia (Figure  2), 
defined both as TcCO2  >  49  mmHg during ≥10% of the 
total recording time (“hypercapnia[2],” p =  0.001) and peak 
TcCO2 > 55 mmHg (“hypercapnia[3],” p = 0.01), while peak 
TcCO2 >  49  mmHg (“hypercapnia[1]”) showed a borderline 
significant association (p =  0.06). Neither the definition of 
hypercapnia suggested by the American Academy for Sleep 
Medicine (AASM) (“hypercapnia[4]”: TcCO2 > 55 mmHg for 
≥10  min or increase in TcCO2 ≥  10  mmHg in comparison 
to an awake supine value to a value exceeding 50 mmHg for 
≥10  min) nor hypoxemia were associated with respiratory 
events (p =  0.15 and p =  0.11, respectively). Similar results 
FigUre 3 | event-free survival. Event-free survival: time to the composite endpoint ICU admission or death. “hypercapnia[2]”: TcCO2 > 49 mmHg during ≥10% of 
the total recording time; “hypercapnia[3]”: peak TcCO2 > 55 mmHg.
FigUre 2 | cumulative incidence of respiratory events requiring icU admission. “hypercapnia[2]”: TcCO2 > 49 mmHg during ≥10% of the total recording 
time; “hypercapnia[3]”: peak TcCO2 > 55 mmHg.
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were found exploring the event (mortality or ICU admission)-
free survival of the patients (p =  0.005 for “hypercapnia[2]” 
definition and p =  0.02 for the “hypercapnia[3]” definition, 
Figure 3).
However, using “hypercapnia[2]” as a diagnostic criterion 
identified almost twofold inefficiently ventilated patients as 
compared with the “hypercapnia[3]” criterion.
DiscUssiOn
We report the first data on the prognostic value of different 
tools to identify residual hypoventilation in mechanically ven-
tilated neuromuscular patients. Analyzing an unselected NMD 
population, we found that inefficiently ventilated patients are at 
increased risk of mortality or ICU admission when compared 
5Ogna et al. Hypoventilation in Ventilated Neuromuscular Patients
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with efficiently ventilated patients. Comparing two monitoring 
techniques, we observed marked differences in the detection rate 
of residual hypoventilation and showed that hypercapnia was sig-
nificantly associated with the risk of respiratory events requiring 
ICU admission in this population, while hypoxemia was not. Our 
results have practical consequences for the daily clinical practice, 
since the evaluation of HMV efficiency belongs to the crucial 
tasks in the management of mechanically ventilated patients.
Restrictive respiratory failure represents one of the leading 
causes of morbidity and mortality in NMD (1–5) and manifests 
as hypoventilation, which can be effectively treated by HMV 
(7, 16–18). The evidence supporting the use of HMV in NMD, 
although mostly based on observational studies, is consistent 
suggesting that the treatment for hypoventilation with HMV 
improves clinical symptoms and quality of life and reduces the 
risk of unplanned hospitalization and mortality, compared with 
no ventilation (6–8, 17, 19, 20).
In the absence of scientific evidence supporting the choice of the 
best strategy to assess HMV efficiency, current recommendations 
on the adjustment of HMV repose on expert opinions, indicating 
the correction of hypoventilation as the main objective. Since 
the definition of hypoventilation is neither univocal nor based 
on prognostic studies (1, 15, 21, 22), an additional assumption 
is made by consensus, making the recommendations even more 
delicate. As such, the European SomnoNIV Group suggests an 
algorithm for monitoring HMV, which includes oximetry as the 
first screening step to identify patients who require further noc-
turnal investigations, and suggests a mean nocturnal SpO2 over 
90% for at least 90% of the total recording time as a goal (9). For 
its part, the AASM recommend in its 2010 best clinical practice 
guidelines to adapt the ventilator support if hypoventilation is 
present for ≥10 min (14).
Our results support the choice of correcting hypoventilation 
as a therapeutic goal, given that hypercapnia – and thus residual 
hypoventilation – seems to be significantly associated with 
the risk of respiratory events in the following few years. In the 
meantime, our data underline once more the lack of sensitivity 
of SpO2 to identify nocturnal hypoventilation in NMD patients. 
In contrast to chronic obstructive pulmonary disease (COPD), 
NMD patients mostly suffer from exclusive restrictive respiratory 
failure without ventilation–perfusion mismatch (23). As a con-
sequence, NMD patients have higher baseline PaO2 values than 
COPD patients, being on the flat portion of the oxyhemoglobin 
dissociation curve, so that the small decrease in PaO2 occurring 
during alveolar hypoventilation is poorly reflected by changes in 
the SpO2 (24, 25).
Recent evidence showed that TcCO2 can be an accurate proxy 
for PaCO2 in long-term mechanically ventilated patients, with the 
advantage to detect episodes of transient hypoventilation, that are 
not detected by punctual blood gazes (10, 11). Our findings add 
to this evidence, suggesting that TcCO2 monitoring may also have 
a prognostic interest in stable, home-ventilated NMD patients. 
The use of TcCO2 opens the possibility to assess the ventilation’s 
efficacy directly and repeated at home, allowing a simplification 
in the management of HMV. However, despite the recent tech-
nical improvements of capnometry devices, TcCO2 accuracy is 
strongly dependent on appropriate handling and knowledge of 
the equipment and procedure (10).
The main limitation of our study is linked to its retrospective 
design, which does not allow to conclude on a causative role of 
residual hypoventilation in the observed increased morbidity. 
Although inefficiently ventilated patients may reasonably have an 
increased respiratory frailty and, thus, be prone to develop severe 
respiratory failure even after a minor infectious event, it is in 
effect possible that residual hypoventilation represents a marker 
of a more severe disease stage rather than an independent risk 
factor for future morbidity, even if we could observe no differ-
ence in the severity of disease between the study groups (Table 2). 
TaBle 2 | Disease severity according to the study subgroup.
hypercapnia[2]+ hypercapnia[2]− hypercapnia[3]+ hypercapnia[3]−
Parameters
Number of patients 15 40 9 46
Age (years) 27 [23.5–31] 29.5 [25–37] 29 [26–30] 28 [25–37]
Weight (kg) 37.0 [28.8–53.0] 48.0 [38.8–60.8] 37.0 [28.5–61.0] 46.5 [38.0–60.0]
BMI (kg/m2) 14.5 [10.4–17.6]a 18.7 [15.5–24.6] 12.3 [10.3–18.4] 17.5 [15.4–24.4]
respiratory parameters
VC sitting (%pred) 10 [7.5–29] 13 [7–25.5] 10 [8.5–36] 12.5 [7–24]
VC supine (%pred) 6 [5–9] 6 [5–21] 6 [5–8] 11 [5–21.5]
PI max (cmH2O) 10 [7–23.5] 14 [2–27] 10.5 [8–21] 12 [2.5–27]
PE max (cmH2O) 10 [7.5–24] 10 [3–24] 10.5 [9–21] 10 [3.5–24]
Mechanical ventilation
Volumetric mode (N, %) 10 (66.7%) 30 (75.0%) 7 (77.8%) 33 (71.7%)
Tracheostomy (N, %) 7 (46.7%) 21 (52.5%) 5 (55.6%) 23 (50.0%)
Daily HMV duration (h) 21.0 [9.0–24.0] 24.0 [11.2–24.0] 23.0 [9.0–24.0] 24.0 [9.0–24.0]
Values are expressed as N (%) of median [interquartile range].
ap < 0.05.
BMI, body mass index; VC, vital capacity; %pred, percentage of the predicted value; PI max, maximal inspiratory pressure; PE max, maximal expiratory pressure; HMV, home 
mechanical ventilation.
“hypercapnia[2]”: TcCO2 > 49 mmHg during ≥10% of the total recording time; “hypercapnia[3]”: peak TcCO2 > 55 mmHg.
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cOnclUsiOn
Our data show for the first time that residual hypoventilation, 
assessed by capnometry, is significantly associated with negative 
outcomes in adult ventilated NMD patients, while simple oxi-
metry is not. These findings may have practical consequences on 
the strategies used to assess HMV efficiency in NMD patients 
and provide support for an appropriately designed trial using 
capnography to investigate its predictive capacity for negative 
outcomes in NMD.
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